About Sunesis Pharmaceuticals, Inc
As of February 24, 2021, Sunesis Pharmaceuticals, Inc. was acquired by Viracta Therapeutics, Inc., in a reverse merger transaction. Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of hematologic and solid cancers. Its lead product candidate is vecabrutinib, a non-covalent inhibitor of Bruton’s tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and other B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; various other partnered programs, such as TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, an anti-cancer quinolone derivative that intercalates DNA and inhibits topoisomerase II. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California. Address: 395 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Sunesis Pharmaceuticals, Inc News and around…
Latest news about Sunesis Pharmaceuticals, Inc (SNSS) common stock and company :
Gainers GameStop Corp. (NYSE: GME) shares surged 103.9% to close at $91.71 on Wednesday after the stock spiked on heavy volume. ...
Gainers Dynatronics (NASDAQ:DYNT) stock rose 63.28% to $2.09 during Wednesday's after-market session. Dynatronics's trading ...
A slew of healthcare stocks is moving on Wednesday in reaction to company-specific catalysts. Sunesis Rises On Hopes of Completion of ...
Gainers Novo Integrated Sciences, Inc. (NASDAQ: NVOS) shares jumped 193.3% to $11.00. Novo Integrated Sciences, on Tuesday, ...
Gainers Novo Integrated Sciences, Inc. - Common Stock (NASDAQ:NVOS) shares moved upwards by 183.54% to $11.31 during ...
Midway through trading Wednesday, the Dow traded up 0.90% to 31,820.21 while the NASDAQ rose 0.54% to 13,537.51. The S&P also rose, ...
Following the market opening Wednesday, the Dow traded down 0.28% to 31,450.55 while the NASDAQ fell 1.2% to 13,303.70. The S&P also ...
Gainers Novo Integrated Sciences, Inc. - Common Stock (NASDAQ:NVOS) stock moved upwards by 371.58% to $18.81 during ...
Gainers Solid Biosciences Inc. (NASDAQ: SLDB) shares surged 41.8% to close at $9.74 on above-average session volume. TimkenSteel ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips An analyst upgrade is the near-term catalyst, but for Sunesis Pharmaceuticals, it's really about patents in oncology and an impending merger with Viracta. The post SNSS Stock: Why Sunesis Pharmaceuticals Is Soaring Today appeared first on InvestorPlace. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next Potential Winner It doesn’t matter if you have $500 in savings or $5 million. Do this now. #1 Play to Profit from Biden's Presidency
Toward the end of trading Tuesday, the Dow traded down 0.19% to 31,461.29 while the NASDAQ fell 1.43% to 13,340.01. The S&P also ...
Gainers Sunesis Pharmaceuticals (NASDAQ:SNSS) stock rose 25.84% to $4.48 during Tuesday's regular session. Trading ...
Midway through trading Tuesday, the Dow traded down 0.48% to 31,369.07 while the NASDAQ fell 1.96% to 13,267.36. The S&P also fell, ...
Gainers Yunhong CTI Ltd. (NASDAQ: CTIB) shares jumped 64.1% to $3.8899. Vascular Biogenics Ltd. (NASDAQ: VBLT) gained 37.7% to ...
Upgrades Exane BNP Paribas upgraded the previous rating for NatWest Group PLC (NYSE:NWG) from Underperform to Neutral. ...
Following the market opening Tuesday, the Dow traded down 0.29% to 31,431.18 while the NASDAQ fell 1.21% to 13,368.87. The S&P also ...
Gainers Vascular Biogenics (NASDAQ:VBLT) shares moved upwards by 28.25% to $2.86 during Tuesday's pre-market ...
Gainers Vascular Biogenics Ltd. (NASDAQ: VBLT) rose 67.3% to $3.73 in pre-market trading. Vascular Biogenics, on Monday, announced ...
Sunesis Pharmaceuticals Inc(NASDAQ:SNSS) merger partner,Viracta Therapeutics Incannounces that the U.S. ...
This morning 533 companies reached new 52-week highs. Intriguing Points: The largest company on a market ...
Thursday's morning session saw 641 companies set new 52-week highs. Noteworthy Highlights: Tesla ...
During Monday's morning session, 286 stocks hit new 52-week highs. Areas of Interest: The company with the ...
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Sunesis Pharmaceuticals, Inc. (NasdaqGS: SNSS) with Viracta Therapeutics, Inc. pursuant to which Sunesis shareholders will end up owning just 14% of the combined company, subject to adjustment. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.
Gainers NeuroMetrix (NASDAQ:NURO) stock rose 60.46% to $3.45 during Monday's after-market session. Trading volume for this ...
Gainers Moleculin Biotech (NASDAQ:MBRX) shares moved upwards by 47.43% to $1.15 during Tuesday's pre-market session. ...
Gainers Onconova Therapeutics, Inc. (NASDAQ: ONTX) rose 51.4% to $0.439 in pre-market trading after climbing over 11% on Monday. ...
Gainers China Automotive Systems, Inc. (NASDAQ: CAAS) shares surged 174.2% to close at $10.50 on Monday after the company ...
Sunesis Pharmaceuticals, Inc (SNSS) is a NASDAQ Common Stock listed in Biotechnology, Common Stock, Healthcare
